Nomura: Maintains JD HEALTH "Buy" Rating and Raises Target Price to HKD 41.5
I'm PortAI, I can summarize articles.
野村發佈研報稱，維持京東健康 “買入” 評級，目標價由 31 港元上調至 41.5 港元，將京東健康 2025 及 2026 財年的收入預測分別上調 2% 及 3%。京東健康 2024 財年下半年收入同比增長 13%，分別超出市場及該行預測 1%;非國際財務報告準則營運利潤率提高 0.4 個百分點至 3.4%，超出該行預測 0.2 個百分點;非國際財務報告準則淨利潤同比增長 27%，分別超出市場及該行預估 15% 及 6%。
智通財經 APP 獲悉，野村發佈研報稱，維持京東健康 (06618)“買入” 評級，目標價由 31 港元上調至 41.5 港元，將京東健康 2025 及 2026 財年的收入預測分別上調 2% 及 3%。京東健康 2024 財年下半年收入同比增長 13%，分別超出市場及該行預測 1%;非國際財務報告準則營運利潤率提高 0.4 個百分點至 3.4%，超出該行預測 0.2 個百分點;非國際財務報告準則淨利潤同比增長 27%，分別超出市場及該行預估 15% 及 6%。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments